echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: When advanced liver cancer is treated with ICI, the occurrence of treatment-related adverse reactions indicates a good prognosis!

    Eur J Cancer: When advanced liver cancer is treated with ICI, the occurrence of treatment-related adverse reactions indicates a good prognosis!

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In multiple studies of patients treated with immune checkpoint inhibitors (ICI), the occurrence of treatment-related adverse events (trAE) is closely related to clinical outcomes; but whether this relationship exists in patients with hepatocellular carcinoma (HCC) Not sure


    immunity

    This study aims to explore the correlation between adverse events related to ICI treatment and the clinical prognosis of HCC patients


    We included 406 patients with unresectable or advanced HCC who were treated with ICI


    In this study cohort, did trAE2 affect OS and PFS?

    In this study cohort, did trAE2 affect OS and PFS?

    Among these 406 patients, 325 (80%) Barcelona clinical liver cancer (BCLC) stage C HCC patients mostly received ICI monotherapy (n=258, 64%), of which 228 (56.


    The occurrence of trAE2 was associated with longer OS (16.


    In the multi-institution cohort, is there any effect of trAE2 on OS and PFS?

    In the multi-institution cohort, is there any effect of trAE2 on OS and PFS?

    In a multi-institution cohort of 357 patients with similar characteristics, most patients also received ICI monotherapy (n=304, 85%)


    The occurrence of trAE2 is longer related to OS (23.


    The occurrence of trAE2 is related to the improvement of the prognosis of HCC patients receiving ICI treatment in clinical trials and clinical practice.


    Original source:

    Pinato David J,Marron Thomas U,Mishra-Kalyani Pallavi Shruti et al.


    Related-toxicity and Improved Treatment outcome in hepatocellular from Cancer Immunotherapy: AN Evidence from the FDA

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.